Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income (2016 - 2025)

Ironwood Pharmaceuticals' Net Income history spans 16 years, with the latest figure at -$83.4 million for Q4 2025.

  • For Q4 2025, Net Income fell 3797.65% year-over-year to -$83.4 million; the TTM value through Dec 2025 reached -$56.1 million, down 6041.84%, while the annual FY2025 figure was $115.1 million, 12984.89% up from the prior year.
  • Net Income for Q4 2025 was -$83.4 million at Ironwood Pharmaceuticals, down from $40.0 million in the prior quarter.
  • Across five years, Net Income topped out at $391.3 million in Q2 2021 and bottomed at -$1.1 billion in Q2 2023.
  • The 5-year median for Net Income is $30.3 million (2022), against an average of -$27.2 million.
  • The largest YoY upside for Net Income was 2839.53% in 2025 against a maximum downside of 3797.65% in 2025.
  • A 5-year view of Net Income shows it stood at $41.4 million in 2021, then surged by 177.04% to $114.6 million in 2022, then plummeted by 299.1% to -$228.3 million in 2023, then surged by 100.99% to $2.3 million in 2024, then plummeted by 3797.65% to -$83.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Net Income are -$83.4 million (Q4 2025), $40.0 million (Q3 2025), and $23.6 million (Q2 2025).